About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04952974

B-cell Chronic Lymphoid Malignancies Markers

Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated). The diagnosis of these malignancies ...

Lead sponsor: University Hospital, Strasbourg, France•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Laurent MAUVIEUX, MD, PhD

CONTACT

33 3 88 12 75 27 [email protected]

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90 [email protected]

Sponsors

Lead Sponsor

University Hospital, Strasbourg, France

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies
•patients that gave their informed consent for the conservation of blood or bone marrow cells (primary objective 1)
•patients that gave their informed consent for the retrospective use of their clinical and biological data

Exclusion Criteria

•patients under guardianship or curatorship
•patients who did not gave their consent for the use of their cells and/or data

Related studies

RECRUITINGPhase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

RECRUITINGPhase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

RECRUITINGPhase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

NCT06548152 · Chronic Lymphocytic Leukemia

RECRUITINGPhase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 7, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment420

Start dateJun 2021

Last updatedJul 7, 2021

Condition

Chronic Lymphocytic Leukemia Marginal Zone Lymphoma Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Mantle Cell Lymphoma Hairy Cell Leukemia+1 more

Locations shown

Hematology Laboratory - Strasbourg University Hospitals

Strasbourg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions